Elevated SARS-COV-2-specific immunoglobulin M (IgM) levels indicated poor clinical outcomes in covid patients, reveals research conducted by a team of scientists from the Huazhong University of Science and Technology, Wuhan, China. Highlighting the importance of this new finding, the  researchers said that it indicates strong association between immunoglobulins and outcome in patients with COVID-19. The profile of SARS-COV-2-specific IgGs also might be useful for future epidemiological investigations of Covid-19 therapies. The researchers said that they had observed the peaking of SARS-COV-2-specific IgM levels in the 4th week after the onset of COVID-19 while serum IgG levels rose earlier and remained high up to the 8th week. More importantly, the study, published in International Journal of General Medicine, pointed out that the patients with COVID-19 who had high IgM or IgG levels exhibited significantly lower overall survival.